Profile Details

Contact

★★★★★

☆☆☆☆☆

USD 90 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Pari Jafari

Australia

USD 90 /hr

Scientific Advisor with PhD and 10+ years of global experience in Medical Device, Pharma, Clinical Research Organisation

Profile Summary

Medical/Scientific Affairs professional holding a Ph.D. degree in pharmacology with extensive academic and industry experience across various therapies. Proven track record of medical management and clinical research development within various medical organisations (Pharmaceuticals and Medical Device). Highly driven and skilled in working effectively and independently with cross-functional clients in global and regional projects (APAC, ANZ, Europe and the USA). Recognized by Medtronic for strong business acumen and ability to establish and maintain relationships with Key Opinion Leaders (Clients).

Subject Matter Expertise

• ★ Pharmacology
• ★ Clinical Research
• ★ Medical Affairs
• ☆ Medical Sciences
• ☆ Clinical Trials
• ☆ Pharmaceutical Industry
• ☆ Psychopharmacology
• ☆ Medical Writing
• ☆ Scientific Writing
• ☆ Science Communication
• ☆ Medical Device
• ☆ Schizophrenia
• ☆ Preclinical Research
• ☆ Scientific Research
• ☆ Project Management
• ☆ Neuropharmacology
• ☆ Neuroscience
• ☆ Mental Health
• ☆ Cognitive Neuroscience
• ☆ Pharmaceutical Management
• ☆ Clinical Evaluation Report (CER)
• ☆ Post-Market Clinical Followup
• ☆ Clinical Trial Protocol Writing
• ☆ Medical Device Literature Reviews
• ☆ Medical device writing

Services

• Consulting
• Product development
• Writing
• Research

Consulting Market research, Feasibility study

Product development Formulation & development

Writing Journal article, Review article, Regulatory documents, Educational content

Research Internet research, Evidence-based answers, Secondary data compilation, Literature search

Work Experience

Medical affairs and Clinical Science Professional/Medical Science Liaison

Medtronic

January 2018 - August 2020

Clinical Study Start-up Specialist

IQVIA

September 2017 - December 2017

Clinical Start-up and Regulatory Specialist (Medical writer/Medical Communication)

Syneos Health (Previously INCResearch)

September 2015 - August 2017

Clinical Research Professional (Study Manager for Pharmaceutical trials)

PRA Health Sciences

May 2013 - September 2015

Medical Science Liaison

Illawarra Health and Medical Research Institute

May 2011 - May 2013

Research Scientist

Wollongong University

January 2007 - June 2012

Senior Clinical Science Associate

Health Management and Economic Research Center - Isfahan University

September 2004 - September 2006

Education

PhD - Pharmacology

Wollongong University

January 2009 - June 2012

Master of Science in Medicinal and Pharmaceutical Chemistry - Research

Wollongong University

January 2007 - November 2008

University of Isfahan

Bachelor of Chemistry

October 2000 - June 2004

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

(2013). In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia . PloS one.

(2012). Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio . BMC pharmacology.

(2012). Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects . Journal of Neurochemistry.

(2006). Mathematical model for determination of colloid osmotic pressure: The role of albumin-globulin ratio. Journal of Research in Medical Science. Journal of Research in Medical Science.

CONFERENCE PAPER

(2012). Development of novel antipsychotic drugs with lower obesogenic effects. The 32nd Annual Meeting of The Australian Neuroscience Society.

CONFERENCE ABSTRACT

(2011). Development of novel antipsychotic drugs based on olanzapine that display reduced weight gain and metabolic side effects. 24th European Congress of Neuropsychopharmacology.

(2011). In vivo pharmacological evaluation of novel olanzapine analogues in rat: Potential novel antipsychotic drugs with lower obesogenic effect. 3rd European Conference on Schizophrenia Research.